Rhythm Pharmaceuticals, Inc.
RYTM · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $3 | $3 | $2 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $4 | $3 | $1 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 68.1% | 227.6% | 649.5% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 89.7% | 88% | 91% | 81% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -183% | -217.6% | -737.1% | -2,170.4% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -200.3% | -238.5% | -766.2% | -2,207.1% |
| EPS Diluted | -4.34 | -3.2 | -3.51 | -1.37 |
| % Growth | -35.6% | 8.8% | -156.2% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | $0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |